Merck & Co., Inc. MRK reported first-quarter 2017 earnings of 88 cents per share, which beat the Zacks Consensus Estimate of 83 cents. However, earnings declined 1.1% from the year-ago period. View photos Merck’s shares rallied …
Bristol-Myers Squibb Co said it would buy privately held IFM Therapeutics for an upfront payment of $300 million, as the drugmaker looks to bolster its cancer portfolio after losing ground to Merck & Co's rival treatment Keytruda. Aug 3 …
After months of headlines about astronomical drug prices, a funny thing’s happening — drug costs are plummeting. Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.